Bridgeway Capital Management’s Adicet Bio ACET Stock Holding History

Bridgeway Capital Management’s Portfolio ACET Stock Details ACET Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$743K	Buy	+85,959	New	+$677K	0.01%	789
2026 Q1	–	Sell	-56,350	Closed	-$474K	–	1224
2025 Q4	$474K	Hold	56,350	–	–	0.01%	829
2025 Q3	$730K	Hold	56,350	–	–	0.02%	744
2025 Q2	$550K	Hold	56,350	–	–	0.01%	761
2025 Q1	$681K	Sell	56,350 -7,813	-12%	-$112K	0.02%	692
2024 Q4	$988K	Buy	64,163 +10,938	+21%	+$206K	0.02%	673
2024 Q3	$1.23M	Buy	53,225 +41,269	+345%	+$924K	0.03%	632
2024 Q2	$231K	Buy	11,956 +3,843	+47%	+$103K	0.01%	1024
2024 Q1	$305K	Buy	8,113 +4,688	+137%	+$194K	0.01%	1036
2023 Q4	$104K	Sell	3,425 -12,150	-78%	-$265K	﹤0.01%	1235
2023 Q3	$341K	Buy	+15,575	New	+$550K	0.01%	984
2021 Q3	–	Sell	-1,250	Closed	-$206K	–	1283
2021 Q2	$206K	Sell	1,250 -268	-18%	-$54.6K	﹤0.01%	1258
2021 Q1	$318K	Hold	1,518	–	–	0.01%	1214
2020 Q4	$341K	Hold	1,518	–	–	0.01%	1081
2020 Q3	$289K	Hold	1,518	–	–	0.01%	1083
2020 Q2	$366K	Buy	+1,518	New	+$298K	0.01%	966
2019 Q4	–	Sell	-848	Closed	-$840K	–	1304
2019 Q3	$840K	Hold	848	–	–	0.01%	774
2019 Q2	$969K	Hold	848	–	–	0.01%	746
2019 Q1	$648K	Hold	848	–	–	0.01%	933
2018 Q4	$819K	Hold	848	–	–	0.01%	810
2018 Q3	$1.44M	Hold	848	–	–	0.01%	736
2018 Q2	$869K	Buy	+848	New	+$913K	0.01%	928

Other funds holding ACET

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

Bridgeway Capital Management's ACET Position: Q2 2026 in Review

Bridgeway Capital Management opened a new position in Adicet Bio (ACET) in Q2 2026: 85,959 shares worth $743K. The stake represents 0.01% of the portfolio and ranks #789 among its holdings. This is a return to the name: Bridgeway Capital Management previously reported a position in ACET as recently as Q4 2025.

Bridgeway Capital Management first reported a position in ACET in Q2 2018 and has held it in 22 quarters since. The position peaked at $1.44M in Q3 2018. 56 funds tracked by Wall St. Rank hold ACET as of Q2 2026.

Bridgeway Capital Management held 85,959 shares of Adicet Bio worth $743K as of Q2 2026.
Adicet Bio was a new Bridgeway Capital Management position in Q2 2026.
Adicet Bio made up 0.01% of Bridgeway Capital Management's portfolio in Q2 2026, its #789 holding.
Bridgeway Capital Management first reported a position in Adicet Bio in Q2 2018 and has held it in 22 quarters since.
Bridgeway Capital Management's Adicet Bio position peaked at $1.44M in Q3 2018.
56 funds tracked by Wall St. Rank held Adicet Bio as of Q2 2026.

Based on Bridgeway Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.